Is PT-141 (Bremelanotide) Legal in Texas?

The Short Answer: PT-141 Is Legal in Texas With a Prescription

Bremelanotide is a federally approved drug and is not a controlled substance, so possessing or using it in Texas with a valid prescription is entirely lawful. Texas does not layer on additional state-level restrictions beyond the federal framework. What determines legality in practice is the pathway through which you obtain it: FDA-approved Vyleesi, a licensed 503A compounding pharmacy, or an FDA-registered 503B outsourcing facility.

No Texas statute specifically restricts or schedules bremelanotide. The Texas Controlled Substances Act (Health and Safety Code Chapter 481) does not list bremelanotide or its analogues. The Drug Enforcement Administration has not scheduled it under the Controlled Substances Act. That combination gives Texas prescribers and patients a relatively clear compliance path.

Why This Question Is Complicated Anyway

The confusion around legality arises because bremelanotide started life as a research compound and was sold for years in a gray-market "research chemical" form. Since the June 2019 FDA approval of Vyleesi, that gray area largely collapsed for clinical use. Purchasing raw bremelanotide powder labeled "not for human use" remains legally ambiguous and carries real risk, including unknown purity and no physician oversight.

The clean legal path is a prescription. Everything outside that path carries some degree of legal or safety exposure.

Federal Framework: FDA Approval and What It Covers

The FDA approved Vyleesi (bremelanotide injection, 1.75 mg/0.3 mL) on June 21, 2019, making it the second FDA-approved pharmacotherapy for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] The approval was based on two Phase 3 randomized controlled trials, RECONNECT Studies A and B (combined N=1,267), in which bremelanotide produced statistically significant improvements on the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm score versus placebo (P<0.001 for both co-primary endpoints). [2]

Mechanism of Action

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds primarily to MC3R and MC4R in the central nervous system, modulating dopaminergic and noradrenergic pathways thought to govern sexual desire. This central mechanism distinguishes it from PDE5 inhibitors, which act peripherally on vascular smooth muscle. [3]

Off-Label Use in Men

The FDA approval covers premenopausal women only. Prescribing bremelanotide to men or postmenopausal women is off-label. Off-label prescribing is legal and common in the United States; the FDA does not prohibit physicians from prescribing approved drugs for unapproved uses at their clinical discretion. Texas Medical Board rules align with this federal norm. A physician prescribing bremelanotide off-label in Texas should document the clinical rationale in the patient record.

Is Bremelanotide a Controlled Substance?

No. The DEA has not placed bremelanotide in any schedule under 21 U.S.C. § 812. [4] This means no DEA prescriber registration number is required specifically to prescribe it, and no state-mandated prescription monitoring program (PMP) reporting applies to bremelanotide in Texas. Texas uses the PMP Awareness Network (PMP AWARxE) for Schedule II-V substances; bremelanotide falls outside that reporting obligation.

Texas State Law: What the State Actually Says

Texas does not have a separate statute governing bremelanotide. Legal analysis of this compound in Texas therefore reduces to three state-level frameworks.

Texas Medical Practice Act

The Texas Medical Practice Act (Occupations Code Chapter 151-165) governs prescribing standards. A Texas-licensed physician may prescribe bremelanotide if a legitimate patient-physician relationship exists, a good-faith medical evaluation has been conducted, and the prescription is issued for a legitimate medical purpose. Prescribing to a patient the physician has never evaluated, or prescribing without any documented clinical rationale, risks discipline under Texas Medical Board (TMB) Rule 190.8. [5]

Texas State Board of Pharmacy Rules

The Texas State Board of Pharmacy (TSBP) regulates pharmacies dispensing to Texas patients. A Texas-licensed pharmacy may dispense FDA-approved Vyleesi without restriction beyond standard prescription verification. Compounded bremelanotide requires additional compliance steps described in the next section.

Telehealth Prescribing in Texas

Texas Senate Bill 1107 (2017) and subsequent TMB rulemaking allow synchronous audio-video telehealth encounters to satisfy the good-faith exam requirement. A Texas patient can therefore receive a bremelanotide prescription from a licensed telehealth provider without an in-person office visit, provided the encounter includes real-time two-way communication and the prescriber can document a clinical assessment. [6] Asynchronous "questionnaire-only" prescribing for bremelanotide remains a gray area under TMB rules and is not recommended.

Compounded Bremelanotide in Texas: 503A vs. 503B

Compounded bremelanotide is frequently offered by telehealth clinics. Understanding the legal framework here is worth the extra detail, because the rules are more nuanced than for the branded product.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding pharmacies that prepare medications for individual patients based on valid prescriptions. A 503A pharmacy may compound a drug that contains an FDA-approved active pharmaceutical ingredient (API) like bremelanotide, provided:

1. A valid, patient-specific prescription exists.
2. The compound is not essentially a copy of a commercially available product (i.e., there must be a clinical reason the commercial product does not meet the patient's needs).
3. The API meets USP/NF standards or comes from an FDA-registered source.
4. The pharmacy holds a valid Texas pharmacy license and complies with TSBP Chapter 562 and USP Chapter 797.

The "essentially a copy" restriction is the most frequently cited concern. If a prescriber wants 1.75 mg bremelanotide subcutaneous injection, that is functionally identical to Vyleesi, and a 503A pharmacy compounding that exact formulation may face FDA scrutiny. A prescriber can document a legitimate clinical difference, such as a different concentration, diluent, or delivery mechanism, to support the compounded prescription. [7]

503B Outsourcing Facilities

Section 503B outsourcing facilities are FDA-registered, state-licensed facilities that may compound without patient-specific prescriptions and may sell to healthcare providers in larger quantities. They are subject to current Good Manufacturing Practice (cGMP) standards. A 503B facility may compound bremelanotide if it is not on the FDA's Category 1 Difficult-to-Compound list and if compounding the drug does not present a demonstrable safety risk. [8]

As of the date of this article, bremelanotide does not appear on the FDA's 503B Bulks List (the affirmative list of bulk substances that 503B facilities may use) nor on the Category 1 "do not compound" list. That ambiguity means a 503B facility compounding bremelanotide operates in a less clearly defined space than one compounding a bulk substance that has received explicit FDA evaluation and inclusion. Texas patients receiving bremelanotide from a 503B facility should ask whether the facility is FDA-registered and confirm its current compliance status. [9]

The FDA Bulk Substances List and Peptide Scrutiny

The FDA has been progressively tightening oversight of compounded peptides. In October 2023, the FDA proposed a rule that would restrict compounding of certain peptides, citing concerns about safety data. Semaglutide and other GLP-1 agents drew the most attention, but the agency's scrutiny extends to the broader peptide category. Bremelanotide has an FDA-approved branded form, which arguably makes it more defensible than unapproved peptides, but also means the FDA can cite the "essentially a copy" doctrine more readily. Texas prescribers and patients should monitor FDA guidance updates from 2025 onward for any reclassification. [10]

HealthRX Legal Access Framework for Bremelanotide in Texas:

| Access Path | Legal? | Conditions | |---|---|---| | Branded Vyleesi via Texas pharmacy | Yes | Valid TX prescription; labeled indication or documented off-label rationale | | Compounded via licensed 503A TX pharmacy | Generally yes | Valid prescription; documented clinical differentiation from Vyleesi; USP-grade API | | Compounded via FDA-registered 503B facility | Conditionally | Facility must be FDA-registered; bremelanotide not on FDA "do not compound" list | | Raw powder from research chemical vendor | No (for human use) | Not for human use labeling; no physician oversight; purity unverified | | Imported from overseas pharmacy | No | Violates FD&C Act import provisions absent specific FDA enforcement discretion |

How to Get PT-141 (Bremelanotide) Legally in Texas

The practical steps are straightforward once the regulatory framework is understood.

Step 1: Find a Licensed Texas Prescriber

Any Texas-licensed physician, nurse practitioner, or physician assistant with prescriptive authority can prescribe bremelanotide. Sexual health specialists, urologists, gynecologists, and hormone therapy clinics are the most common prescribers. Telehealth platforms licensed in Texas can also initiate the prescription after a synchronous video evaluation.

The prescriber should take a clinical history that includes the nature of the sexual dysfunction, duration of symptoms, ruling out of underlying causes (thyroid dysfunction, depression, relationship factors, medications that reduce libido), and a review of contraindications including uncontrolled hypertension, since bremelanotide transiently increases blood pressure by an average of 2 mmHg systolic and 1 mmHg diastolic, with peak effects at 12 minutes post-injection. [1]

Step 2: Obtain the Prescription

After the clinical evaluation, the prescriber issues a written or electronic prescription. For branded Vyleesi, any licensed Texas pharmacy can fill it. For compounded bremelanotide, the prescriber should direct the prescription to a TSBP-licensed 503A pharmacy or work with the telehealth platform's affiliated 503B-registered pharmacy.

Step 3: Confirm Pharmacy Credentials

Before paying for a compounded product, verify two things. First, confirm the pharmacy holds a current Texas pharmacy license (searchable at the TSBP public license lookup). Second, ask whether the facility is 503A or 503B. For 503B, verify FDA registration at the FDA's outsourcing facility database. [9]

Step 4: Understand the Dosing Protocol

FDA-approved dosing for Vyleesi is 1.75 mg injected subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Patients should not use more than one dose within 24 hours. The most common adverse effects in the RECONNECT trials were nausea (40.0% bremelanotide vs. 1.2% placebo), flushing (20.4% vs. 1.6%), and injection-site reactions (13.2% vs. 2.8%). [2] Nausea typically resolves within 12 hours without treatment.

Step 5: Report Adverse Events

Patients in Texas experiencing unexpected adverse events from either branded or compounded bremelanotide should report to the FDA MedWatch program and notify their prescriber. [11] Reports of adverse events from compounded products are particularly valuable because they inform the FDA's ongoing safety review of compounded peptides.

Clinical Considerations for Texas Prescribers

Contraindications to Know

Bremelanotide is contraindicated in patients with known cardiovascular disease, uncontrolled hypertension, or those taking naltrexone (because bremelanotide is a melanocortin agonist and naltrexone interacts with the endogenous opioid system in ways that may alter the drug's effect profile). Patients with hyperpigmentation risk should be counseled: focal hyperpigmentation of the face, breasts, and gums occurred in 1% of patients in the RECONNECT trials receiving repeated dosing over 52 weeks. [2]

Drug Interactions

Indomethacin, a commonly used NSAID, slows bremelanotide absorption and reduces the area under the curve (AUC) by approximately 10%. Naltrexone used concomitantly reduces bremelanotide AUC by approximately 35%. The prescribing information recommends avoiding concurrent naltrexone use. [1] Patients on naloxone for opioid use disorder programs should discuss this interaction with their prescriber before starting bremelanotide.

Monitoring During Treatment

There are no required laboratory monitoring parameters for bremelanotide in the FDA labeling. Blood pressure should be measured at baseline in all patients; those with borderline hypertension (systolic 130-139 mmHg) warrant closer follow-up given the transient pressor effect. Prescribers may choose to monitor blood pressure after the first dose in the clinical setting for higher-risk patients.

What the Guidelines Say

The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 consensus process statements describe bremelanotide as an appropriate treatment option for HSDD in premenopausal women after ruling out contributing factors, including hormonal deficiency, relationship distress, and mood disorders. [12] The American College of Obstetricians and Gynecologists (ACOG) notes in its FAQ on female sexual dysfunction that FDA-approved pharmacotherapy options for HSDD include both flibanserin and bremelanotide, and that shared decision-making should guide selection. [13]

The ISSWSH process statements note: "Bremelanotide is recommended for the treatment of acquired, generalized HSDD in premenopausal women who have no distress about their level of sexual desire and who have not yet tried pharmacotherapy." This framing matters for Texas prescribers writing documentation to support medical necessity.

Research-Chemical Bremelanotide: The Risk You Take Without a Prescription

Before the 2019 FDA approval, bremelanotide was sold openly by research chemical vendors as a "not for human use" compound. Some vendors continue to sell it in this form. Purchasing this product in Texas carries risks on several levels.

No purity verification exists. Third-party testing of research peptides frequently identifies incorrect concentrations, bacterial endotoxin contamination, and in some cases, entirely different compounds. Preparing and self-injecting an unverified compound carries direct health risk. From a legal standpoint, while bremelanotide is not a controlled substance, selling or purchasing adulterated or misbranded drugs remains a federal offense under the FD&C Act. Texas Health and Safety Code Chapter 431 (the Texas Food, Drug, and Cosmetic Act) mirrors federal adulteration and misbranding prohibitions. The practical enforcement risk to individual patients is low, but the health risk is real.

The FDA inspection of peptide vendors has increased since 2022. Receiving a shipment of research-chemical bremelanotide from an overseas supplier passes through U.S. Customs and Border Protection, which is authorized to seize unapproved drug imports. [10]

Frequently Asked Questions